Form 4: Amneal EVP Awarded Equity Grants for Performance

Amneal Pharmaceuticals' Executive Vice President, Andrew S. Boyer, received grants of restricted stock units and performance-based restricted stock units.

Summary

• Andrew S. Boyer, Executive Vice President of Amneal Pharmaceuticals, Inc. (AMRX), was granted 65,359 Restricted Stock Units (RSUs) and 65,359 Performance-Based Restricted Stock Units (PSUs) on March 2, 2026.
• Each RSU represents a contingent right to receive one share of the Issuer's Class A Common Stock.
• The RSUs are scheduled to vest in four equal annual installments, with the first installment beginning on March 2, 2027.
• Each PSU represents a contingent right to receive one share of the Issuer's Class A Common Stock, with the reported number representing the maximum potential shares.
• The PSUs are performance-based, vesting contingent on Amneal's Class A Common Stock achieving specific average closing price targets over a three-year performance period.
• The number of shares received from PSUs can range from 0% to 200% of the target number (65,359 shares), based on performance.
• Any earned PSUs will vest in full on February 28, 2029, which is the last day of the performance period.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices designed to align management incentives with long-term shareholder value, though it introduces potential future dilution.

Positives

• The equity grants align the Executive Vice President's long-term financial interests with those of the shareholders, incentivizing sustained company performance.
• Performance-based units directly link executive compensation to the achievement of specific stock price targets, potentially driving shareholder value.

Negatives

• The issuance of new shares upon vesting of these units could lead to future dilution for existing shareholders.
• The performance-based nature of the PSUs introduces uncertainty regarding the actual number of shares that will ultimately vest.

Risks

• Failure to meet the specified average closing price targets for the Class A Common Stock could result in 0% vesting for the performance-based restricted stock units.
• Market volatility and general economic conditions could impact the company's stock price, affecting the value and vesting of the performance-based awards.

Future Outlook

The grants indicate a forward-looking compensation strategy designed to incentivize long-term executive performance tied to the company's stock price appreciation over a three-year period, with vesting extending up to four years for RSUs.

Industry Context

StockSavvy.ai notes that the granting of restricted stock units and performance-based restricted stock units is a common practice in the pharmaceutical industry and broader corporate landscape for executive compensation. This structure aims to retain key talent and align management incentives with shareholder value creation over multi-year periods, a standard approach to long-term incentive plans.

Comparison to Industry Standards

• The use of both time-based (RSUs) and performance-based (PSUs) equity awards is a standard practice in executive compensation across industries, including pharmaceuticals, to balance retention with performance incentives.
• The vesting schedule for RSUs (four equal annual installments) and the three-year performance period for PSUs are typical durations for long-term incentive plans in companies comparable to Amneal Pharmaceuticals, such as Teva Pharmaceutical Industries Ltd. or Viatris Inc., which also utilize similar equity-based compensation structures to motivate executives and align with strategic goals.

Stakeholder Impact

• Shareholders: Potential for future dilution upon vesting of the equity awards, but also benefit from increased alignment of executive interests with long-term stock performance.
• Employees: No direct impact mentioned, but executive compensation practices can influence overall company culture and compensation philosophy.

Next Steps

• The Restricted Stock Units will begin to vest in four equal annual installments starting March 2, 2027.
• The Performance-Based Restricted Stock Units will be evaluated against stock price targets over a three-year period, with any earned units vesting on February 28, 2029.

Key Dates

Keywords

Amneal Pharmaceuticals, AMRX, Restricted Stock Units, Performance-Based Restricted Stock Units, Executive Compensation, Insider Transaction, Equity Grant, Stock Options, Corporate Governance